929048-72-6

Upstream product

• 1249705-88-1 methyl 3,5-dichloromandelate 
• 55954-24-0 methyl 2-(3,5-dichlorophenyl)acetate 
• 929048-70-4 methyl 2-(3,5-dichlorophenyl)-2-mesyloxy-acetate 

Downstream Products

• 929048-76-0 N-(3-methoxy-benzyl)-N-methyl-2-(3,5-dichlorophenyl)-2-(phenylsulfanyl)-acetamide 
• 929048-77-1 N-(3-methoxybenzyl)-N-methyl-2-(3,5-dichlorophenyl)-2-(phenylsulfinyl)-acetamide 
• 929048-75-9 2-(3,5-dichlorophenyl)-2-(phenylsulfanyl)-acetic acid 

Relevant academic research and scientific papers

SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF

The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

MINERALOCORTICOID RECEPTOR ANTAGONISTS

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophyl

Isoquinolines as IGF-1R Inhibitors

Compounds of the formula (I): were synthesized. In at least one embodiment, they were found to down-regulate or inhibit the expression or function of the IGF-1 receptor.

ISOQUINOLINES AS IGF-1R INHIBITORS

Compounds of the formula (I) were synthesized. They were found to down- regulate or inhibit the expression or function of the IGF-I receptor.